Vyndamax Shortage Update: What Patients Need to Know in 2026

If you've been searching online for "Vyndamax shortage 2026," you're probably concerned about whether your next refill will be available. The short answer: there is no FDA-listed drug shortage for Vyndamax. But that doesn't mean access is easy. This article explains the current state of Vyndamax availability, what has changed in 2026, and what patients should do to protect their treatment continuity.

Is Vyndamax in Shortage Right Now?

As of 2026, the FDA's Drug Shortage Database does not list tafamidis (Vyndamax) as a product in shortage. Pfizer, the manufacturer, has not issued any public shortage notification. Vyndamax continues to be manufactured and distributed through specialty pharmacy channels.

The access problems patients experience are structural, not supply-based:

• Specialty pharmacy-only distribution means it's not available at retail stores
• Prior authorization requirements create delays of 1–4 weeks
• Insurance denials and appeals add additional weeks to first access
• Plan network requirements may restrict which specialty pharmacy you can use

The Big 2026 Change: Vyndaqel Is Being Discontinued

The most significant 2026 development for tafamidis patients is the discontinuation of Vyndaqel. Pfizer has announced that Vyndaqel (tafamidis meglumine, taken as four 20-mg capsules once daily) will no longer be available after 2025. Vyndamax (one 61-mg capsule daily) is bioequivalent to the 80-mg Vyndaqel dose and will be the only tafamidis formulation going forward.

If you were previously prescribed Vyndaqel 80 mg, your cardiologist can switch you to Vyndamax 61 mg — which provides equivalent drug exposure in a single, more convenient capsule. This is not a therapeutic change; it is the same medicine in a different formulation.

Has Vyndamax Ever Been in Shortage?

Vyndamax has not appeared on the FDA's Drug Shortage Database since its approval in May 2019. Because it is a specialty-distributed orphan drug with a small but defined patient population, Pfizer has been able to maintain consistent manufacturing and supply. This is in contrast to many generic medications that experience demand-driven shortages.

The Competitive Landscape: New Alternatives in 2026

While Vyndamax itself isn't in shortage, the ATTR-CM treatment landscape has expanded significantly. Two new FDA-approved options now give patients and providers more choices:

• Attruby (acoramidis) — FDA-approved November 2024; another TTR stabilizer taken twice daily
• Amvuttra (vutrisiran) — FDA-approved for ATTR-CM March 2025; a TTR silencer given as a quarterly injection

These alternatives mean that even if you face Vyndamax access delays, there are now FDA-approved alternatives your cardiologist can discuss. This is a major change from 2019–2024 when Vyndaqel/Vyndamax were the only approved options.

What Patients Should Do to Protect Their Access

1. Refill early. Don't wait until your last capsule to request a refill. Specialty pharmacies require advance notice for specialty medications. Start the refill process at least 2 weeks before you run out.
2. Monitor your PA renewal dates. Most prior authorizations for Vyndamax need to be renewed annually. Ask your cardiologist's office to track PA expiration dates so you're not caught off-guard.
3. Stay enrolled in VynAssist. Pfizer's VynAssist program (myVynAssist.com) proactively supports patients with refill management, PA renewals, and access coordination.
4. If your Vyndaqel prescription hasn't been switched to Vyndamax yet, contact your cardiologist to update the prescription — Vyndaqel will not be available after 2025.

How medfinder Helps Patients Stay on Therapy

medfinder helps patients who are experiencing access delays by contacting pharmacies on their behalf to identify which ones can fill their Vyndamax prescription. If your usual specialty pharmacy is experiencing a processing backlog or if you're new to Vyndamax and need to find a pharmacy, medfinder streamlines the search process.

Bottom Line

Vyndamax is not in shortage in 2026. Supply is stable, and Pfizer continues to manufacture and distribute it. The access challenges patients face are administrative and financial, not supply-based. If you're having trouble filling your prescription, see our guide to how to find Vyndamax in stock near you for step-by-step help.